SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as investors eagerly await a "game-changer" partnership announcement, hinted at by management as coming prior to the new year. This potential alliance, especially in the federal and sovereign AI sectors, is fueling strong bullish sentiment for a significant revenue boost and short squeeze, though some in the community express skepticism over its timing and market impact.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending due to a proposed merger with Applied Digital's cloud computing business, aiming to pivot into an AI GPU compute platform named ChronoScale. This potential transformation from a medical device company to an AI infrastructure player is driving market conversation. The community is actively discussing the implications of this shift, with many anticipating a significant re-rating given exposure to AI and a low share float, though some express concerns regarding shareholder dilution.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is currently trending due to its exceptionally low public float, which is generating significant retail investor interest and speculation for a potential short squeeze. The community is actively discussing the stock's potential for rapid upward movement, with many eyeing key resistance levels and recent strong profitability metrics as drivers, despite some acknowledgment of past revenue trends. This micro-cap's tight share structure and increasing volume are fueling intense conversation around its parabolic breakout potential.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies ($OPEN) is currently trending amidst a polarized community, with recent positive pending home sales data providing a potential tailwind for the real estate sector. Bulls are optimistic about new management's AI-driven strategy and targeted profitability by 2026, viewing current price weakness as a tax-loss selling opportunity for 'smart money'. However, bears remain vocal, dismissing the stock as overvalued with a flawed business model, predicting further declines as the debate over its long-term viability intensifies.

Intelligent Living Application Group, Inc. engages in the manufacturing and selling of mechanical locksets. It focuses in producing mechanical locksets including locksets for outdoors such as main entrances and gates and indoors. The firm offers a range of original design manufacturer door locksets to various customer segments with classic to contemporary looks, functions and colors. The company was founded by Po Wang Hui in 1981 and is headquartered in Hong Kong.

Intelligent Living Application Group Inc

Intelligent Living Application Group (ILAG) is attracting significant attention, notably after a recent reverse stock split and regaining Nasdaq compliance, alongside reported increases in revenue and gross profit. The community is actively discussing the stock's reduced share float and a new equity incentive for its CEO, with many anticipating the potential for parabolic moves similar to other high-flying 'Hong Kong' and 'Chinese' stocks.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is generating buzz following the FDA approval of an oral GLP-1 medication from Novo Nordisk, igniting community speculation about a potential distribution partnership given prior discussions. This development occurs amid ongoing discussions regarding a proposed bill impacting compounded weight-loss drugs, creating polarized sentiment between long-term growth believers and those focused on recent price pressures and high short interest.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to compelling preliminary Phase 3 data showing a significant reduction in breast cancer recurrence rates and a strategic extension of insider share lock-ups through September 2026. The community is actively discussing a potential short squeeze, fueled by the stock's low float, extremely high cost-to-borrow rates, and substantial trading volume, with many anticipating significant long-term gains and potential acquisition interest for its promising GLSI-100 immunotherapy.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye Global is at the center of a divided community discussion following recent earnings, which, despite meeting expectations, did little to stem the stock's ongoing decline. Investors are actively debating the long-term potential of its autonomous driving technology and partnerships, such as with lidar provider Innoviz, against a backdrop of market skepticism and intense competition. While many lament the stock's performance, a counter-narrative sees the current levels as an opportune entry point given the company's strong fundamentals and future prospects in ADAS and robotaxis.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN is trending as the community eagerly awaits updates on its MariTide weight-loss drug, with intense discussions around its efficacy, tolerability, and competitive positioning against rival therapies. The company's recent strong earnings and positive trial results for its Repatha cholesterol treatment, coupled with strategic direct-to-consumer pricing initiatives, are also driving significant investor interest.

Global X Funds - Global X Uranium ETF

Global X Uranium ETF

The Global X Uranium ETF is trending as the community increasingly links burgeoning AI energy demand to a critical need for stable nuclear power, solidifying uranium's strategic resource status. Investors are actively discussing the recent inclusion of uranium on the U.S. critical minerals list and a persistent supply deficit, further amplified by continuous buying from investment vehicles and supportive government policies. This confluence of factors underpins a strong long-term bullish outlook for the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VNDA Today is the day, I personale valuate the most, Even that febr. PDUFA is better - on paper. But ( if...) todays approval has much more potential and appeal to partnership or buyout from level 1 companies. Its All about GLP-1. Novo is a perfect match with New approved pill and 30% nausea. Any investment in US will benefit Them acc. to tariffs. To partner up with VNDA, they will set back Eli Lilly, who actually need Tradipitant more, to catch up with Novo. On the other hand, Eli Lilly can use the rest of pipeline more than Novo. But there are more players on level II, who is desperate to get a share of the weight loss market. All GLP-1 have nausea problems. Remember 12 GLP-1 are approved so far. VNDA will be a hot pie here, if they cant solve the nausea problem. I guess there might be a line of offers coming in - within weeks. Cross fingers for an approval today. Tradipitant is worth much more than indicated. A $1B partnership is just a grip in the pocket.

UkNic

Del Pi

Felix Hantel

Uschi Long

Mink

StockTwits For Android 

Vanda Pharmaceuticals Inc

 Today is the day, I personale valuate the most, Even that febr. PDUFA is better - on paper. But ( if...) todays approval has much more potential and appeal to partnership or buyout from level 1 companies. Its All about GLP-1. Novo is a perfect match with New approved pill and 30% nausea. Any investment in US will benefit Them acc. to tariffs. To partner up with VNDA, they will set back Eli Lilly, who actually need Tradipitant more, to catch up with Novo. On the other hand, Eli Lilly can use the rest of pipeline more than Novo. But there are more players on level II, who is desperate to get a share of the weight loss market. All GLP-1 have nausea problems. Remember 12 GLP-1 are approved so far. VNDA will be a hot pie here, if they cant solve the nausea problem. I guess there might be a line of offers coming in - within weeks. Cross fingers for an approval today. Tradipitant is worth much more than indicated. A $1B partnership is just a grip in the pocket.

Michael

@Trendrebel I am thinking approval yes. Most GLP-1 N/Vs are transient during start/dose change so it does make sense to use NK1As to manage the nausea problem.

Pastime

StockTwits Web

 I am thinking approval yes. Most GLP-1 N/Vs are transient during start/dose change so it does make sense to use NK1As to manage the nausea problem.